HCC: Updates from ILCA and ESMO 2022

December 06, 2023 • 00:30:22
HCC: Updates from ILCA and ESMO 2022
COR2ED - Oncology Medical Conversation
HCC: Updates from ILCA and ESMO 2022

Dec 06 2023 | 00:30:22

/

Show Notes

In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.

Other Episodes

Episode

March 21, 2025 • 00:26:05
Episode Cover

Best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer

This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.   Dr Rena Callahan and Dr Roberto Salgado...

Listen

Episode

April 25, 2024 • 00:27:48
Episode Cover

Cáncer de pulmón: dificultades en la fase preanalítica y pruebas de biomarcadores

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de pulmón, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones...

Listen

Episode

December 06, 2023 • 00:20:49
Episode Cover

RCC: Treating advanced RCC - The role of VEGFR-TKIs alone or in combination therapy

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Prof. Georg Hutterer, a Urologist from the Medical University of...

Listen